J. Karlsson

发表

B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial

K. Michaëlsson, H. Melhus, L. Lind, 2003, Journal of hypertension.

Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial

H. Melhus, L. Lind, T. Kahan, 2002, Journal of hypertension.

Gender‐specific association between preproendothelin‐1 genotype and reduction of systolic blood pressure during antihypertensive treatment‐‐‐results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA)

K. Michaëlsson, H. Melhus, L. Lind, 2004, Clinical cardiology.

Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

H. Melhus, L. Lind, A. Syvänen, 2004, American journal of hypertension.

Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.

H. Melhus, L. Lind, T. Kahan, 2002, American journal of hypertension.

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients

H. Melhus, L. Lind, T. Kahan, 2001, Journal of hypertension.

A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response.

H. Melhus, L. Lind, A. Syvänen, 2003, Pharmacogenetics.

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors

O. Wallerman, C. Wadelius, H. Melhus, 2004, The Pharmacogenomics Journal.

Beta1‐adrenergic receptor gene polymorphisms and response to Beta1‐adrenergic receptor blockade in patients with essential hypertension

K. Michaëlsson, H. Melhus, L. Lind, 2004, Clinical cardiology.

Transforming growth factor β1 genotype and change in left ventricular mass during antihypertensive treatment–results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (Silvhia)

H. Melhus, L. Lind, A. Syvänen, 2004 .

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial

H. Melhus, L. Lind, P. Hallberg, 2002, Journal of hypertension.

Transforming Growth Factor 1 Genotype and Change in Left Ventricular Mass during Antihypertensive Treatment — Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol

L. Lind, K. Malmqvist, J. Karlsson, 2006 .